Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK plus non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial

被引：2
|
作者：
Ahn, Myung-Ju
Camidge, D. Ross
Tiseo, Marcello
Reckamp, Karen L.
Hansen, Karin Holmskov
Kim, Sang-We
Huber, Rudolf M.
West, Howard Jack
Groen, Harry J. M.
Hochmair, Maximilian J.
Leighl, Natasha B.
Gettinger, Scott N.
Langer, Corey J.
Paz-Ares, Luis G.
Smit, Egbert F.
Kim, Edward S.
Reichmann, William
Kerstein, David
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Univ Colorado Denver, Aurora, CO USA
[3] Univ Hosp Parma, Parma, Italy
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Odense Univ Hosp, Odense, Denmark
[6] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[7] Univ Hosp Munich, Thorac Oncol Ctr Munich, Munich, Germany
[8] Swedish Canc Inst, Seattle, WA USA
[9] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands
[10] Otto Wagner Hosp, Vienna, Austria
[11] Princess Margaret Canc Ctr, Toronto, ON, Canada
[12] Yale Canc Ctr, New Haven, CT USA
[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA
[14] Hosp Octubre, Dept Med Oncol, Madrid, Spain
[15] Vrije Univ VU Med Ctr, Amsterdam, Netherlands
[16] Levine Canc Inst, Charlotte, NC USA
[17] ARIAD Pharmaceut, Cambridge, MA USA
[18] Seoul Natl Univ Hosp, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e20503
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20503
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L
    Popat, S.
    Kim, H. R.
    Ahn, M-J.
    Yang, J. C.
    Han, J-Y.
    Hochmair, M. J.
    Lee, K. H.
    Delmonte, A.
    Garcia Campelo, M. R.
    Kim, D-W.
    Griesinger, F.
    Felip, E.
    Califano, R.
    Spira, A.
    Gettinger, S. N.
    Tiseo, M.
    Lin, H. M.
    Liu, Y.
    Vranceanu, F.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2021, 32 : S954 - S955
  • [22] Intracranial efficacy of brigatinib (BRG) in patients (Pts) With crizotinib (CRZ)-refractory anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and baseline CNS metastases
    Ou, S-H. I.
    Tiseo, M.
    Camidge, R.
    Ahn, M-J.
    Huber, R. M.
    Hochmair, M. J.
    Kim, S-W.
    West, H. L.
    Reckamp, K. L.
    Molina, J. R.
    Liu, G.
    Delmonte, A.
    Viteri, S.
    Bearz, A.
    Summers, Y.
    Reichmann, W.
    Kerstein, D.
    Gettinger, S. N.
    Kim, D-W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Design of ALTA-1 L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)positive non-small cell lung cancer (NSCLC).
    Tiseo, Marcello
    Popat, Sanjay
    Gettinger, Scott N.
    Peters, Solange
    Haney, Jeff
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [24] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
    Griesinger, Frank
    Camidge, D. Ross
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James Chih-Hsin
    Han, Ji Youn
    Hochmair, Maximilian
    Lee, Hyeong
    Delmonte, Angelo
    Garcia Compelo, Maria Rosario
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spire, Alexander
    Gettinger, Scott N.
    Tiseo, Marcello
    Lin, Huamao M.
    Ni, Quanhong
    Zhang, Pingkuan
    Popat, Sanjay
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
  • [25] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L
    Yang, James C. H.
    Kim, Hye R.
    Ahn, Myung-Ju
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki H.
    Delmonte, Angelo
    Garcia Campelo, Maria R.
    Kim, Dong-Wan
    Felip, Enriqueta
    Califano, Raffaele
    Spira, Alexander
    Gettinger, Scott
    Tiseo, Marcello
    Haney, Jeff
    Kerstein, David
    Popat, Sanjay
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Phase III ALTA-3 study of brigatinib (BRG) vs alectinib (ALC) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) that progressed on crizotinib (CRZ)
    Popat, S.
    Liu, G.
    Lu, S.
    Song, G.
    Samnotra, V.
    Yang, J. C-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Activity and safety of brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Phase (ph) 1/2 trial results.
    Langer, Corey J.
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Dorer, David J.
    Rivera, Victor M.
    Haluska, Frank G.
    Kerstein, David
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Brigatinib (BRG) in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Bazhenova, L.
    Gettinger, S.
    Langer, C.
    Salgia, R.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G.
    Haney, J.
    Rivera, V.
    Haluska, F.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC).
    Choi, Briana
    Alkhatib, Nimer S.
    Pae, Elizabeth
    Babiker, Hani M.
    Garland, Linda L.
    Henglefelt, Alyssa
    McBride, Ali
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L)
    Garcia Campelo, Maria Rosario
    Lin, Huamao M.
    Zhu, Yanyan
    Perol, Maurice
    Jahanzeb, Mohammad
    Popat, Sanjay
    Zhang, Pingkuan
    Camidge, D. Ross
    LUNG CANCER, 2021, 155 : 68 - 77
12345